Abstract: The influenza B strain is epidemiologically relevant in the pediatric population. Immunogenic priming of children with influenza B vaccine adjuvanted with an oil-in-water emulsion primes an immune response to a booster vaccine comprising influenza B virus antigen from a differing strain or lineage, irrespective of whether the booster comprises an adjuvant.

Abstract: A first intracellular pathogen in a biological sample that may contain more than one intracellular pathogen is studied by a method comprising the steps of (i) contacting the sample with a population of cells in the presence of an agent inhibiting the reproduction of a second intracellular pathogen; (ii) incubating the cells under conditions that permit the reproduction of the first intracellular pathogen; and (iii) testing material arising from step (ii) for the first intracellular pathogen.

Abstract: A first intracellular pathogen in a biological sample that may contain more than one intracellular pathogen is studied by a method comprising the steps of (i) contacting the sample with a population of cells in the presence of an agent inhibiting the reproduction of a second intracellular pathogen; (ii) incubating the cells under conditions that permit the reproduction of the first intracellular pathogen; and (iii) testing material arising from step (ii) for the first intracellular pathogen.

Abstract: The influenza B strain is epidemiologically relevant in the pediatric population. Immunogenic priming of children with influenza B vaccine adjuvanted with an oil-in-water emulsion primes an immune response to a booster vaccine comprising influenza B virus antigen from a different strain or lineage, irrespective of whether the booster comprises an adjuvant.

Abstract: Vaccines of the invention include at least four influenza virus strains. In some embodiments, the vaccines are produced in cell culture rather than in eggs. In some embodiments, the vaccines include an adjuvant. In some embodiments, the vaccines are not split or whole virion vaccines, but are live or purified glycoprotein vaccines. In some embodiments, the vaccines contain substantially the same mass of hemagglutinin (HA) for each of the influenza virus strains. In some embodiments, the four strains will include two influenza A virus strains and two influenza B virus strains (‘A-A-B-B’). In other embodiments, the four strains will include three influenza A virus strains and one influenza B virus strain (‘A-A-A-B’).

Abstract: A first intracellular pathogen in a biological sample that may contain more than one intracellular pathogen is studied by a method comprising the steps of (i) contacting the sample with a population of cells in the presence of an agent inhibiting the reproduction of a second intracellular pathogen; (ii) incubating the cells under conditions that permit the reproduction of the first intracellular pathogen; and (iii) testing material arising from step (ii) for the first intracellular pathogen.

Abstract: An influenza vaccine includes an increased amount of H3N2 antigen relative to the normal dose. In a typical embodiment, the vaccine includes hemagglutinins from an A/H1N1 strain, an A/H3N2 strain, and a B strain, wherein (i) the weight ratio of H3N2:H1N1 hemagglutinin is greater than 1 and (ii) the weight ratio of H3N2:B hemagglutinin is greater than 1. In such a vaccine the weight ratio of H1N1:B hemagglutinin will normally be 1. For example, a vaccine may contain hemagglutinin at 15 ?g for A/H1N1, 30 ?g for A/H3N2 and 15 ?g for B.

Abstract: Vaccines of the invention include at least four influenza virus strains. In some embodiments, the vaccines are produced in cell culture rather than in eggs. In some embodiments, the vaccines include an adjuvant. In some embodiments, the vaccines are not split or whole virion vaccines, but are live or purified glycoprotein vaccines. In some embodiments, the vaccines contain substantially the same mass of hemagglutinin (HA) for each of the influenza virus strains. In some embodiments, the four strains will include two influenza A virus strains and two influenza B virus strains (‘A-A-B-B’). In other embodiments, the four strains will include three influenza A virus strains and one influenza B virus strain (‘A-A-A-B’).